Protein clearance mechanisms of alpha-synuclein and amyloid-beta in Lewy body disorders

International Journal of Alzheimer's Disease

Volumn , Issue , 2012, Pages

  Deleidi, Michela ^a   Maetzler, Walter ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; AMYLOID BETA PROTEIN;

ALZHEIMER DISEASE; ASTROCYTE; AUTOIMMUNITY; AUTOPHAGY; BLOOD BRAIN BARRIER; CEREBROSPINAL FLUID; DIFFUSE LEWY BODY DISEASE; DISEASE COURSE; ENZYME MECHANISM; FLUID TRANSPORT; HUMAN; MICROGLIA; PHAGOCYTE; PRIORITY JOURNAL; REVIEW; UNFOLDED PROTEIN RESPONSE;

EID: 84869039156     PISSN: None     EISSN: 20900252     Source Type: Journal    
DOI: 10.1155/2012/391438     Document Type: Review

References (134)

1. Kahle P. J., α -Synucleinopathy models and human neuropathology: similarities and differences. Acta Neuropathologica 2008 115 1 87 95 2-s2.0-36949031267 10.1007/s00401-007-0302-x (Pubitemid 350238669)
2. Gasser T., Molecular pathogenesis of Parkinson disease: insights from genetic studies. Expert Reviews in Molecular Medicine 2009 11, article e22 2-s2.0-69149089036 10.1017/S1462399409001148
3. Scholz S. W., Houlden H., Schulte C., Sharma M., Li A., Berg D., Melchers A., Paudel R., Gibbs J. R., Simon-Sanchez J., Paisan-Ruiz C., Bras J., Ding J., Chen H., Traynor B. J., Arepalli S., Zonozi R. R., Revesz T., Holton J., Wood N., Lees A., Oertel W., Wüllner U., Goldwurm S., Pellecchia M. T., Illig T., Riess O., Fernandez H. H., Rodriguez R. L., Okun M. S., Poewe W., Wenning G. K., Hardy J. A., Singleton A. B., Gasser T., SNCA variants are associated with increased risk for multiple system atrophy. Annals of Neurology 2009 65 5 610 614 2-s2.0-67249139655 10.1002/ana.21685
4. Lippa C. F., Duda J. E., Grossman M., Hurtig H. I., Aarsland D., Boeve B. F., Brooks D. J., Dickson D. W., Dubois B., Emre M., Fahn S., Farmer J. M., Galasko D., Galvin J. E., Goetz C. G., Growdon J. H., Gwinn-Hardy K. A., Hardy J., Heutink P., Iwatsubo T., Kosaka K., Lee V. M. Y., Leverenz J. B., Masliah E., McKeith I. G., Nussbaum R. L., Olanow C. W., Ravina B. M., Singleton A. B., Tanner C. M., Trojanowski J. Q., Wszolek Z. K., DLB and PDD boundary issues: diagnosis, treatment, molecular pathology, and biomarkers. Neurology 2007 68 11 812 819 2-s2.0-34047223232 10.1212/01.wnl.0000256715.13907.d3 (Pubitemid 46568532)
5. Baba M., Nakajo S., Tu P. H., Tomita T., Nakaya K., Lee V. M. Y., Trojanowski J. Q., Iwatsubo T., Aggregation of α -synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies. American Journal of Pathology 1998 152 4 879 884 2-s2.0-0031941058 (Pubitemid 28173348)
6. Gelb D. J., Oliver E., Gilman S., Diagnostic criteria for Parkinson disease. Archives of Neurology 1999 56 1 33 39 2-s2.0-0032937059 10.1001/archneur.56.1.33 (Pubitemid 29046907)
7. Emre M., Aarsland D., Brown R., Burn D. J., Duyckaerts C., Mizuno Y., Broe G. A., Cummings J., Dickson D. W., Gauthier S., Goldman J., Goetz C., Korczyn A., Lees A., Levy R., Litvan I., McKeith I., Olanow W., Poewe W., Quinn N., Sampaio C., Tolosa E., Dubois B., Clinical diagnostic criteria for dementia associated with Parkinson's disease. Movement Disorders 2007 22 12 1689 1707 2-s2.0-35348939603 10.1002/mds.21507 (Pubitemid 47597592)
8. McKeith I. G., Dickson D. W., Lowe J., Emre M., O'Brien J. T., Feldman H., Cummings J., Duda J. E., Lippa C., Perry E. K., Aarsland D., Arai H., Ballard C. G., Boeve B., Burn D. J., Costa D., Del Ser T., Dubois B., Galasko D., Gauthier S., Goetz C. G., Gomez-Tortosa E., Halliday G., Hansen L. A., Hardy J., Iwatsubo T., Kalaria R. N., Kaufer D., Kenny R. A., Korczyn A., Kosaka K., Lee V. M. Y., Lees A., Litvan I., Londos E., Lopez O. L., Minoshima S., Mizuno Y., Molina J. A., Mukaetova-Ladinska E. B., Pasquier F., Perry R. H., Schulz J. B., Trojanowski J. Q., Yamada M., Diagnosis and management of dementia with Lewy bodies: third report of the DLB consortium. Neurology 2005 65 12 1863 1872 2-s2.0-33745659407 10.1212/01.wnl.0000187889.17253.b1 (Pubitemid 43970103)
9. Jellinger K. A., Seppi K., Wenning G. K., Clinical and neuropathological correlates of Lewy body disease (multiple letters). Acta Neuropathologica 2003 106 2 188 189 2-s2.0-0037592395 10.1007/s00401-003-0721-2 (Pubitemid 36869255)
10. Boller F., Mizutani T., Roessmann U., Gambetti P., Parkinson disease, dementia, and Alzheimer disease: clinicopathological correlations. Annals of Neurology 1980 7 4 329 335 2-s2.0-0018897531 (Pubitemid 10112826)
11. Braak H., Rüb U., Jansen Steur E. N. H., Del Tredici K., de Vos R. A. I., Cognitive status correlates with neuropathologic stage in Parkinson disease. Neurology 2005 64 8 1404 1410 2-s2.0-17644426053 (Pubitemid 40570509)
12. Hughes A. J., Daniel S. E., Blankson S., Lees A. J., A clinicopathologic study of 100 cases of Parkinson's disease. Archives of Neurology 1993 50 2 140 148 2-s2.0-0027465936 (Pubitemid 23054795)
13. Maetzler W., Liepelt I., Berg D., Progression of Parkinson's disease in the clinical phase: potential markers. The Lancet Neurology 2009 8 12 1158 1171 2-s2.0-71849104690 10.1016/S1474-4422(09)70291-1
14. Ballard C., Ziabreva I., Perry R., Larsen J. P., O'Brien J., McKeith I., Perry E., Aarsland D., Differences in neuropathologic characteristics across the Lewy body dementia spectrum. Neurology 2006 67 11 1931 1934 2-s2.0-33845709899 10.1212/01.wnl.0000249130.63615.cc (Pubitemid 44967366)
15. Brooks D. J., Imaging amyloid in Parkinson's disease dementia and dementia with Lewy bodies with positron emission tomography. Movement Disorders 2009 24 supplement 2 S742 S747 2-s2.0-72849109343 10.1002/mds.22581
16. Maetzler W., Liepelt I., Reimold M., Reischl G., Solbach C., Becker C., Schulte C., Leyhe T., Keller S., Melms A., Gasser T., Berg D., Cortical PIB binding in Lewy body disease is associated with Alzheimer-like characteristics. Neurobiology of Disease 2009 34 1 107 112 2-s2.0-62149140954 10.1016/j.nbd.2008.12.008
17. Gerlach M., Maetzler W., Broich K., Hampel H., Rems L., Reum T., Riederer P., Stöffler A., Streffer J., Berg D., Biomarker candidates of neurodegeneration in Parkinson's disease for the evaluation of disease-modifying therapeutics. Journal of Neural Transmission 2012 119 1 39 52 2-s2.0-79960183832 10.1007/s00702-011-0682-x
18. Hershko A., Ciechanover A., The ubiquitin system. Annual Review of Biochemistry 1998 67 425 479 2-s2.0-0031657807 10.1146/annurev.biochem.67.1.425 (Pubitemid 28411135)
19. Schwartz A. L., Ciechanover A., The ubiquitin-proteasome pathway and pathogenesis of human diseases. Annual Review of Medicine 1999 50 57 74 2-s2.0-0033016291 10.1146/annurev.med.50.1.57 (Pubitemid 29117052)
20. Ciechanover A., Brundin P., The ubiquitin proteasome system in neurodegenerative diseases: sometimes the chicken, sometimes the egg. Neuron 2003 40 2 427 446 2-s2.0-0141987860 10.1016/S0896-6273(03)00606-8 (Pubitemid 37244106)
21. Cuervo A. M., Autophagy: in sickness and in health. Trends in Cell Biology 2004 14 2 70 77 2-s2.0-0442323561 10.1016/j.tcb.2003.12.002 (Pubitemid 38186640)
22. Klionsky D. J., Autophagy. Current Biology 2005 15 8 R282 R283 2-s2.0-23344446037
23. Mizushima N., Autophagy: process and function. Genes and Development 2007 21 22 2861 2873 2-s2.0-36249025723 10.1101/gad.1599207 (Pubitemid 350133435)
24. Martinez-Vicente M., Cuervo A. M., Autophagy and neurodegeneration: when the cleaning crew goes on strike. The Lancet Neurology 2007 6 4 352 361 2-s2.0-33847652900 10.1016/S1474-4422(07)70076-5 (Pubitemid 46367949)
25. Dewitt D. A., Perry G., Cohen M., Doller C., Silver J., Astrocytes regulate microglial phagocytosis of senile plaque cores of Alzheimer's disease. Experimental Neurology 1998 149 2 329 340 2-s2.0-18144453796 10.1006/exnr.1997.6738 (Pubitemid 28115071)
26. Lee C. Y. D., Landreth G. E., The role of microglia in amyloid clearance from the AD brain. Journal of Neural Transmission 2010 117 8 949 960 2-s2.0-77956955758 10.1007/s00702-010-0433-4
27. Takuma K., Fang F., Zhang W., Yan S., Fukuzaki E., Du H., Sosunov A., McKhann G., Funatsu Y., Nakamichi N., Nagai T., Mizoguchi H., Ibi D., Hori O., Ogawa S., Stern D. M., Yamada K., Yan S. S., RAGE-mediated signaling contributes to intraneuronal transport of amyloid- β and neuronal dysfunction. Proceedings of the National Academy of Sciences of the United States of America 2009 106 47 20021 20026 2-s2.0-73949088883 10.1073/pnas.0905686106
28. Fuentealba R. A., Liu Q., Zhang J., Kanekiyo T., Hu X., Lee J. M., Ladu M. J., Bu G., Low-density lipoprotein receptor-related protein 1 (LRP1) mediates neuronal A β 42 uptake and lysosomal trafficking. PLoS ONE 2010 5 7 2-s2.0-77955604553 10.1371/journal.pone.0011884 e11884
29. Koprich J. B., Reske-Nielsen C., Mithal P., Isacson O., Neuroinflammation mediated by IL-1 β increases susceptibility of dopamine neurons to degeneration in an animal model of Parkinson's disease. Journal of Neuroinflammation 2008 5, article 8 2-s2.0-42249115877 10.1186/1742-2094-5-8 (Pubitemid 351546594)
30. Deleidi M., Hallett P. J., Koprich J. B., Chung C. Y., Isacson O., The toll-like receptor-3 agonist polyinosinic:polycytidylic acid triggers nigrostriatal dopaminergic degeneration. Journal of Neuroscience 2010 30 48 16091 16101 2-s2.0-78649745833 10.1523/JNEUROSCI.2400-10.2010
31. Papachroni K. K., Ninkina N., Papapanagiotou A., Hadjigeorgiou G. M., Xiromerisiou G., Papadimitriou A., Kalofoutis A., Buchman V. L., Autoantibodies to α -synuclein in inherited Parkinson's disease. Journal of Neurochemistry 2007 101 3 749 756 2-s2.0-34247402084 10.1111/j.1471-4159.2006. 04365.x (Pubitemid 46633311)
32. Weksler M. E., Relkin N., Turkenich R., LaRusse S., Zhou L., Szabo P., Patients with Alzheimer disease have lower levels of serum anti-amyloid peptide antibodies than healthy elderly individuals. Experimental Gerontology 2002 37 7 943 948 2-s2.0-0036085702 10.1016/S0531-5565(02)00029-3 (Pubitemid 34665486)
33. Brettschneider S., Morgenthaler N. G., Teipel S. J., Fischer-Schulz C., Bürger K., Dodel R., Du Y., Möller H. J., Bergmann A., Hampel H., Decreased serum amyloid β 142 autoantibody levels in Alzheimer's disease, determined by a newly developed immuno-precipitation assay with radiolabeled amyloid β 142 peptide. Biological Psychiatry 2005 57 7 813 816 2-s2.0-20144387251 10.1016/j.biopsych.2004.12.008 (Pubitemid 40487927)
34. Braak H., Del Tredici K., Rüb U., de Vos R. A. I., Jansen Steur E. N. H., Braak E., Staging of brain pathology related to sporadic Parkinson's disease. Neurobiology of Aging 2003 24 2 197 211 2-s2.0-0037333666 10.1016/S0197-4580(02)00065-9 (Pubitemid 36007810)
35. Hallett P. J., McLean J. R., Kartunen A., Langston J. W., Isacson O., α -Synuclein overexpressing transgenic mice show internal organ pathology and autonomic deficits. Neurobiology of Disease 2012 47 2 258 267 2-s2.0-84861706581 10.1016/j.nbd.2012.04.009
36. Kaufmann H., Nahm K., Purohit D., Wolfe D., Autonomic failure as the initial presentation of Parkinson disease and dementia with Lewy bodies. Neurology 2004 63 6 1093 1095 2-s2.0-4644323707 (Pubitemid 39287924)
37. Webb J. L., Ravikumar B., Atkins J., Skepper J. N., Rubinsztein D. C., α -Synuclein is degraded by both autophagy and the proteasome. The Journal of Biological Chemistry 2003 278 27 25009 25013 2-s2.0-0041589248 10.1074/jbc.M300227200 (Pubitemid 37548663)
38. Cuervo A. M., Stafanis L., Fredenburg R., Lansbury P. T., Sulzer D., Impaired degradation of mutant α -synuclein by chaperone-mediated autophagy. Science 2004 305 5688 1292 1295 2-s2.0-4344659685 10.1126/science.1101738 (Pubitemid 39129234)
39. Tofaris G. K., Layfield R., Spillantini M. G., α -Synuclein metabolism and aggregation is linked to ubiquitin-independent degradation by the proteasome. FEBS Letters 2001 509 1 22 26 2-s2.0-0035976835 10.1016/S0014-5793(01)03115-5 (Pubitemid 33153074)
40. Spencer B., Potkar R., Trejo M., Rockenstein E., Patrick C., Gindi R., Adame A., Wyss-Coray T., Masliah E., Beclin 1 gene transfer activates autophagy and ameliorates the neurodegenerative pathology in α -synuclein models of Parkinson's and Lewy body diseases. Journal of Neuroscience 2009 29 43 13578 13588 2-s2.0-70350550208 10.1523/JNEUROSCI.4390-09.2009
41. Martinez-Vicente M., Talloczy Z., Kaushik S., Massey A. C., Mazzulli J., Mosharov E. V., Hodara R., Fredenburg R., Wu D. C., Follenzi A., Dauer W., Przedborski S., Ischiropoulos H., Lansbury P. T., Sulzer D., Cuervo A. M., Dopamine-modified α -synuclein blocks chaperone-mediated autophagy. Journal of Clinical Investigation 2008 118 2 777 778 2-s2.0-38849174979 10.1172/JCI32806 (Pubitemid 351206565)
42. Stefanis L., Larsen K. E., Rideout H. J., Sulzer D., Greene L. A., Expression of A53T mutant but not wild-type α -synuclein in PC12 cells induces alterations of the ubiquitin-dependent degradation system, loss of dopamine release, and autophagic cell death. Journal of Neuroscience 2001 21 24 9549 9560 2-s2.0-0035894855 (Pubitemid 34184043)
43. Tanaka Y., Engelender S., Igarashi S., Rao R. K., Wanner T., Tanzi R. E., Sawa A., Dawson V. L., Dawson T. M., Ross C. A., Inducible expression of mutant α -synuclein decreases proteasome activity and increases sensitivity to mitochondria-dependent apoptosis. Human Molecular Genetics 2001 10 9 919 926 2-s2.0-0035870881 (Pubitemid 32401408)
44. Petrucelli L., O'Farrell C., Lockhart P. J., Baptista M., Kehoe K., Vink L., Choi P., Wolozin B., Farrer M., Hardy J., Cookson M. R., Parkin protects against the toxicity associated with mutant α -synuclein: proteasome dysfunction selectively affects catecholaminergic neurons. Neuron 2002 36 6 1007 1019 2-s2.0-0037137702 10.1016/S0896-6273(02)01125-X (Pubitemid 36044504)
45. Snyder H., Mensah K., Theisler C., Lee J., Matouschek A., Wolozin B., Aggregated and monomeric α -synuclein bind to the S6′ proteasomal protein and inhibit proteasomal function. The Journal of Biological Chemistry 2003 278 14 11753 11759 2-s2.0-0038413759 10.1074/jbc.M208641200 (Pubitemid 36800143)
46. Alvarez-Erviti L., Rodriguez-Oroz M. C., Cooper J. M., Caballero C., Ferrer I., Obeso J. A., Schapira A. H. V., Chaperone-mediated autophagy markers in Parkinson disease brains. Archives of Neurology 2010 67 12 1464 1472 2-s2.0-78149469728 10.1001/archneurol.2010.198
47. Vives-Bauza C., Przedborski S., Mitophagy: the latest problem for Parkinson's disease. Trends in Molecular Medicine 2011 17 3 158 165 2-s2.0-79952451427 10.1016/j.molmed.2010.11.002
48. Geisler S., Holmström K. M., Skujat D., Fiesel F. C., Rothfuss O. C., Kahle P. J., Springer W., PINK1/Parkin-mediated mitophagy is dependent on VDAC1 and p62/SQSTM1. Nature Cell Biology 2010 12 2 119 131 2-s2.0-75949130828 10.1038/ncb2012
49. Michiorri S., Gelmetti V., Giarda E., Lombardi F., Romano F., Marongiu R., Nerini-Molteni S., Sale P., Vago R., Arena G., Torosantucci L., Cassina L., Russo M. A., Dallapiccola B., Valente E. M., Casari G., The Parkinson-associated protein PINK1 interacts with Beclin1 and promotes autophagy. Cell Death and Differentiation 2010 17 6 962 974 2-s2.0-77952242572 10.1038/cdd.2009.200
50. McCoy M. K., Cookson M. R., DJ-1 regulation of mitochondrial function and autophagy through oxidative stress. Autophagy 2011 7 5 531 532 2-s2.0-79955701611 10.4161/auto.7.5.14684
51. Tong Y., Yamaguchi H., Giaime E., Boyle S., Kopan R., Kelleher R. J., Shen J., Loss of leucine-rich repeat kinase 2 causes impairment of protein degradation pathways, accumulation of α -synuclein, and apoptotic cell death in aged mice. Proceedings of the National Academy of Sciences of the United States of America 2010 107 21 9879 9884 2-s2.0-77953090478 10.1073/pnas.1004676107
52. Gómez-Suaga P., Luzón-Toro B., Churamani D., Zhang L., Bloor-Young D., Patel S., Woodman P. G., Churchill G. C., Hilfiker S., Leucine-rich repeat kinase 2 regulates autophagy through a calcium-dependent pathway involving NAADP. Human Molecular Genetics 2012 21 3 511 525 2-s2.0-84862907943 10.1093/hmg/ddr481
53. Mazzulli J. R., Xu Y. H., Sun Y., Knight A. L., McLean P. J., Caldwell G. A., Sidransky E., Grabowski G. A., Krainc D., Gaucher disease glucocerebrosidase and α -synuclein form a bidirectional pathogenic loop in synucleinopathies. Cell 2011 146 1 37 52 2-s2.0-79960009804 10.1016/j.cell.2011.06.001
54. Schmid S. P., Schleicher E. D., Cegan A., Deuschle C., Baur S., Hauser A.-K., Synofzik M., Srulijes K., Brockmann K., Berg D., Maetzler W., Cerebrospinal fluid fatty acids in glucocerebrosidase-associated Parkinson's disease. Movement Disorders 2012 27 2 288 293 2-s2.0-84856975504 10.1002/mds.23984
55. Lee H. J., Patel S., Lee S. J., Intravesicular localization and exocytosis of α -synuclein and its aggregates. Journal of Neuroscience 2005 25 25 6016 6024 2-s2.0-21344456506 10.1523/JNEUROSCI.0692-05.2005 (Pubitemid 40911433)
56. El-Agnaf O. M., Salem S. A., Paleologou K. E., Cooper L. J., Fullwood N. J., α -Synuclein implicated in Parkinson's disease is present in extracellular biological fluids, including human plasma. The FASEB Journal 2003 17 13 1945 1947
57. Mollenhauer B., Locascio J. J., Schulz-Schaeffer W., Sixel-Döring F., Trenkwalder C., Schlossmacher M. G., α -Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study. The Lancet Neurology 2011 10 3 230 240 2-s2.0-79951720856 10.1016/S1474-4422(11)70014-X
58. Cicchetti F., Brownell A. L., Williams K., Chen Y. I., Livni E., Isacson O., Neuroinflammation of the nigrostriatal pathway during progressive 6-OHDA dopamine degeneration in rats monitored by immunohistochemistry and PET imaging. European Journal of Neuroscience 2002 15 6 991 998 2-s2.0-0036459335 10.1046/j.1460-9568.2002.01938.x (Pubitemid 35463634)
59. Sánchez-Pernaute R., Ferree A., Cooper O., Yu M., Brownell A. L., Isacson O., Selective COX-2 inhibition prevents progressive dopamine neuron degeneration in a rat model of Parkinson's disease. Journal of Neuroinflammation 2004 1, article 6 2-s2.0-4344645719 10.1186/1742-2094-1-6 (Pubitemid 39130328)
60. Deleidi M., Isacson O., Viral and inflammatory triggers of neurodegenerative diseases. Science Translational Medicine 2012 4 121 121ps3 2-s2.0-84857225543 10.1126/scitranslmed.3003492
61. Teismann P., Sathe K., Bierhaus A., Leng L., Martin H. L., Bucala R., Weigle B., Nawroth P. P., Schulz J. B., Receptor for advanced glycation endproducts (RAGE) deficiency protects against MPTP toxicity. Neurobiology of Aging 2012 33 10 2478 2490 2-s2.0-84864379214 10.1016/j.neurobiolaging.2011.12. 006
62. Maetzler W., Berg D., Schalamberidze N., Melms A., Schott K., Mueller J. C., Liaw L., Gasser T., Nitsch C., Osteopontin is elevated in Parkinson's disease and its absence leads to reduced neurodegeneration in the MPTP model. Neurobiology of Disease 2007 25 3 473 482 2-s2.0-33847237667 10.1016/j.nbd.2006.10.020
63. Halliday G. M., Stevens C. H., Glia: initiators and progressors of pathology in Parkinson's disease. Movement Disorders 2011 26 1 6 17 2-s2.0-79951499176 10.1002/mds.23455
64. Gu X. L., Long C. X., Sun L., Xie C., Lin X., Cai H., Astrocytic expression of Parkinson's disease-related A53T α -synuclein causes neurodegeneration in mice. Molecular Brain 2010 3 1, article 12 2-s2.0-77951077317 10.1186/1756-6606-3-12
65. Mackenzie I. R. A., Activated microglia in dementia with Lewy bodies. Neurology 2000 55 1 132 134 2-s2.0-0034641287
66. Braak H., Sastre M., Del Tredici K., Development of α -synuclein immunoreactive astrocytes in the forebrain parallels stages of intraneuronal pathology in sporadic Parkinson's disease. Acta Neuropathologica 2007 114 3 231 241 2-s2.0-34547727312 10.1007/s00401-007-0244-3 (Pubitemid 47226149)
67. Lee H. J., Suk J. E., Bae E. J., Lee S. J., Clearance and deposition of extracellular α -synuclein aggregates in microglia. Biochemical and Biophysical Research Communications 2008 372 3 423 428 2-s2.0-44749090147 10.1016/j.bbrc.2008.05.045
68. Hamza T. H., Zabetian C. P., Tenesa A., Laederach A., Montimurro J., Yearout D., Kay D. M., Doheny K. F., Paschall J., Pugh E., Kusel V. I., Collura R., Roberts J., Griffith A., Samii A., Scott W. K., Nutt J., Factor S. A., Payami H., Common genetic variation in the HLA region is associated with late-onset sporadic Parkinson's disease. Nature Genetics 2010 42 9 781 785 2-s2.0-77956646167 10.1038/ng.642
69. Saiki M., Baker A., Williams-Gray C. H., Foltynie T., Goodman R. S., Taylor C. J., Compston D. A. S., Barker R. A., Sawcer S. J., Goris A., Association of the human leucocyte antigen region with susceptibility to Parkinson's disease. Journal of Neurology, Neurosurgery and Psychiatry 2010 81 8 890 891 2-s2.0-77955759020 10.1136/jnnp.2008.162883
70. Kreutzberg G. W., Microglia: a sensor for pathological events in the CNS. Trends in Neurosciences 1996 19 8 312 318 2-s2.0-0030222037 10.1016/0166-2236(96)10049-7 (Pubitemid 26349059)
71. Orr C. F., Rowe D. B., Mizuno Y., Mori H., Halliday G. M., A possible role for humoral immunity in the pathogenesis of Parkinson's disease. Brain 2005 128 11 2665 2674 2-s2.0-27644531857 10.1093/brain/awh625 (Pubitemid 41552950)
72. Maetzler W., Berg D., Synofzik M., Brockmann K., Godau J., Melms A., Gasser T., Hörnig S., Langkamp M., Autoantibodies against amyloid and glial-derived antigens are increased in serum and cerebrospinal fluid of lewy body-associated dementias. Journal of Alzheimer's Disease 2011 26 1 171 179 2-s2.0-80052850843 10.3233/JAD-2011-110221
73. Hong Z., Shi M., Chung K. A., Quinn J. F., Peskind E. R., Galasko D., Jankovic J., Zabetian C. P., Leverenz J. B., Baird G., Montine T. J., Hancock A. M., Hwang H., Pan C., Bradner J., Kang U. J., Jensen P. H., Zhang J., DJ-1 and α -synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease. Brain 2010 133 3 713 726 2-s2.0-77950223687 10.1093/brain/awq008
74. Shi M., Bradner J., Hancock A. M., Chung K. A., Quinn J. F., Peskind E. R., Galasko D., Jankovic J., Zabetian C. P., Kim H. M., Leverenz J. B., Montine T. J., Ginghina C., Kang U. J., Cain K. C., Wang Y., Aasly J., Goldstein D., Zhang J., Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression. Annals of Neurology 2011 69 3 570 580 2-s2.0-79953283868 10.1002/ana.22311
75. Mollenhauer B., Cullen V., Kahn I., Krastins B., Outeiro T. F., Pepivani I., Ng J., Schulz-Schaeffer W., Kretzschmar H. A., McLean P. J., Trenkwalder C., Sarracino D. A., VonSattel J. P., Locascio J. J., El-Agnaf O. M. A., Schlossmacher M. G., Direct quantification of CSF α -synuclein by ELISA and first cross-sectional study in patients with neurodegeneration. Experimental Neurology 2008 213 2 315 325 2-s2.0-49449105990 10.1016/j.expneurol.2008.06.004
76. Tokuda T., Salem S. A., Allsop D., Mizuno T., Nakagawa M., Qureshi M. M., Locascio J. J., Schlossmacher M. G., El-Agnaf O. M. A., Decreased α -synuclein in cerebrospinal fluid of aged individuals and subjects with Parkinson's disease. Biochemical and Biophysical Research Communications 2006 349 1 162 166 2-s2.0-33748325848 10.1016/j.bbrc.2006.08.024 (Pubitemid 44331776)
77. Tokuda T., Qureshi M. M., Ardah M. T., Varghese S., Shehab S. A. S., Kasai T., Ishigami N., Tamaoka A., Nakagawa M., El-Agnaf O. M. A., Detection of elevated levels of α -synuclein oligomers in CSF from patients with Parkinson disease. Neurology 2010 75 20 1766 1772 2-s2.0-78649990079 10.1212/WNL.0b013e3181fd613b
78. Wang Y., Shi M., Chung K. A., Zabetian C. P., Leverenz J. B., Berg D., Srulijes K., Trojanowski J. Q., Lee V. M. Y., Siderowf A. D., Hurtig H., Litvan I., Schiess M. C., Peskind E. R., Masuda M., Hasegawa M., Lin X., Pan C., Galasko D., Goldstein D. S., Jensen P. H., Yang H., Cain K. C., Zhang J., Phosphorylated α -synuclein in Parkinson's disease. Science Translational Medicine 2012 4 121 ra120 2-s2.0-84863164994 10.1126/scitranslmed.3002566
79. Scheuner D., Eckman C., Jensen M., Song X., Citron M., Suzuki N., Bird T. D., Hardy J., Hutton M., Kukull W., Larson E., Levy-Lahad E., Viitanen M., Peskind E., Poorkaj P., Schellenberg G., Tanzi R., Wasco W., Lannfelt L., Selkoe D., Younkin S., Secreted amyloid β -protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. Nature Medicine 1996 2 8 864 870 2-s2.0-16044373524 10.1038/nm0896-864 (Pubitemid 26296755)
80. Mawuenyega K. G., Sigurdson W., Ovod V., Munsell L., Kasten T., Morris J. C., Yarasheski K. E., Bateman R. J., Decreased clearance of CNS β -amyloid in Alzheimer's disease. Science 2010 330 6012, article 1774 2-s2.0-78650678688 10.1126/science.1197623
81. Nixon R. A., Wegiel J., Kumar A., Yu W. H., Peterhoff C., Cataldo A., Cuervo A. M., Extensive involvement of autophagy in Alzheimer disease: an immuno-electron microscopy study. Journal of Neuropathology and Experimental Neurology 2005 64 2 113 122 2-s2.0-14844303381 (Pubitemid 40349309)
82. Yu W. H., Cuervo A. M., Kumar A., Peterhoff C. M., Schmidt S. D., Lee J. H., Mohan P. S., Mercken M., Farmery M. R., Tjernberg L. O., Jiang Y., Duff K., Uchiyama Y., Näslund J., Mathews P. M., Cataldo A. M., Nixon R. A., Macroautophagya novel β -amyloid peptide-generating pathway activated in Alzheimer's disease. Journal of Cell Biology 2005 171 1 87 98 2-s2.0-26444587508 10.1083/jcb.200505082 (Pubitemid 41434604)
83. Nixon R. A., Autophagy, amyloidogenesis and Alzheimer disease. Journal of Cell Science 2007 120 23 4081 4091 2-s2.0-38349046973 10.1242/jcs.019265
84. Boland B., Kumar A., Lee S., Platt F. M., Wegiel J., Yu W. H., Nixon R. A., Autophagy induction and autophagosome clearance in neurons: relationship to autophagic pathology in Alzheimer's disease. Journal of Neuroscience 2008 28 27 6926 6937 2-s2.0-49049096562 10.1523/JNEUROSCI.0800-08.2008
85. Pickford F., Masliah E., Britschgi M., Lucin K., Narasimhan R., Jaeger P. A., Small S., Spencer B., Rockenstein E., Levine B., Wyss-Coray T., The autophagy-related protein beclin 1 shows reduced expression in early Alzheimer disease and regulates amyloid β accumulation in mice. Journal of Clinical Investigation 2008 118 6 2190 2199 2-s2.0-45749114895 10.1172/JCI33585 (Pubitemid 351872337)
86. Lee J. H., Yu W. H., Kumar A., Lee S., Mohan P. S., Peterhoff C. M., Wolfe D. M., Martinez-Vicente M., Massey A. C., Sovak G., Uchiyama Y., Westaway D., Cuervo A. M., Nixon R. A., Lysosomal proteolysis and autophagy require presenilin 1 and are disrupted by Alzheimer-related PS1 mutations. Cell 2010 141 7 1146 1158 2-s2.0-77953913051 10.1016/j.cell.2010.05.008
87. Weller R. O., Yow H. Y., Preston S. D., Mazanti I., Nicoll J. A. R., Cerebrovascular disease is a major factor in the failure of elimination of A β from the aging human brain: implications for therapy of Alzheimer's disease. Annals of the New York Academy of Sciences 2002 977 162 168 2-s2.0-0036450037 (Pubitemid 35418150)
88. Nalivaeva N. N., Fisk L. R., Belyaev N. D., Turner A. J., Amyloid-degrading enzymes as therapeutic targets in Alzheimer's disease. Current Alzheimer Research 2008 5 2 212 224 2-s2.0-42149125510 10.2174/ 156720508783954785 (Pubitemid 351536346)
89. Hawkes C. A., Härtig W., Kacza J., Schliebs R., Weller R. O., Nicoll J. A., Carare R. O., Perivascular drainage of solutes is impaired in the ageing mouse brain and in the presence of cerebral amyloid angiopathy. Acta Neuropathologica 2011 121 4 431 443 2-s2.0-79954623282 10.1007/s00401-011-0801-7
90. Howell S., Nalbantoglu J., Crine P., Neutral endopeptidase can hydrolyze β -amyloid(140) but shows no effect on β -amyloid precursor protein metabolism. Peptides 1995 16 4 647 652 2-s2.0-0029061685 10.1016/0196-9781(95) 00021-B
91. Iwata N., Tsubuki S., Takaki Y., Shirotani K., Lu B., Gerard N. P., Gerard C., Hama E., Lee H. J., Saido T. C., Metabolic regulation of brain A β by neprilysin. Science 2001 292 5521 1550 1552 2-s2.0-0035947207 10.1126/science.1059946 (Pubitemid 32493424)
92. Spillantini M. G., Sicuteri F., Salmon S., Malfroy B., Characterization of endopeptidase 3.4.24.11 (enkephalinase) activity in human plasma and cerebrospinal fluid. Biochemical Pharmacology 1990 39 8 1353 1356 2-s2.0-0025277862 10.1016/0006-2952(90)90012-A (Pubitemid 20119211)
93. Nalivaeva N. N., Fisk L., Kochkina E. G., Plesneva S. A., Zhuravin I. A., Babusikova E., Dobrota D., Turner A. J., Effect of hypoxia/ischemia and hypoxic preconditioning/reperfusion on expression of some amyloid-degrading enzymes. Annals of the New York Academy of Sciences 2004 1035 21 33 2-s2.0-14944380978 10.1196/annals.1332.002 (Pubitemid 40362324)
94. Iwata N., Takaki Y., Fukami S., Tsubuki S., Saido T. C., Region-specific reduction of A β -degrading endopeptidase, neprilysin, in mouse hippocampus upon aging. Journal of Neuroscience Research 2002 70 3 493 500 2-s2.0-0037010286 10.1002/jnr.10390 (Pubitemid 35222386)
95. Nishio C., Yoshida K., Nishiyama K., Hatanaka H., Yamada M., Involvement of cystatin C in oxidative stress-induced apoptosis of cultured rat CNS neurons. Brain Research 2000 873 2 252 262 2-s2.0-0034637296 10.1016/S0006-8993(00) 02540-3 (Pubitemid 30619049)
96. Grubb A., Diagnostic value of analysis of cystatin C and protein HC in biological fluids. Clinical Nephrology 1992 38 supplement 1 S20 S27 2-s2.0-0027058414 (Pubitemid 23092541)
97. Selenica M. L., Wang X., Ostergaard-Pedersen L., Westlind-Danielsson A., Grubb A., Cystatin C reduces the in vitro formation of soluble A β 142 oligomers and protofibrils. Scandinavian Journal of Clinical and Laboratory Investigation 2007 67 2 179 190 2-s2.0-33947133671 10.1080/00365510601009738 (Pubitemid 46410600)
98. Sastre M., Calero M., Pawlik M., Mathews P. M., Kumar A., Danilov V., Schmidt S. D., Nixon R. A., Frangione B., Levy E., Binding of cystatin C to Alzheimer's amyloid β inhibits in vitro amyloid fibril formation. Neurobiology of Aging 2004 25 8 1033 1043 2-s2.0-2942737051 10.1016/j. neurobiolaging.2003.11.006 (Pubitemid 38798065)
99. Hansson S. F., Andréasson U., Wall M., Skoog I., Andreasen N., Wallin A., Zetterberg H., Blennow K., Reduced levels of amyloid- β -binding proteins in cerebrospinal fluid from Alzheimer's disease patients. Journal of Alzheimer's Disease 2009 16 2 389 397 2-s2.0-60349101411 10.3233/JAD-2009-0966
100. Simonsen A. H., McGuire J., Podust V. N., Hagnelius N. O., Nilsson T. K., Kapaki E., Vassilopoulos D., Waldemar G., A novel panel of cerebrospinal fluid biomarkers for the differential diagnosis of Alzheimer's disease versus normal aging and frontotemporal dementia. Dementia and Geriatric Cognitive Disorders 2007 24 6 434 440 2-s2.0-36448997798 10.1159/000110576 (Pubitemid 350175903)
101. Kaeser S. A., Herzig M. C., Coomaraswamy J., Kilger E., Selenica M. L., Winkler D. T., Staufenbiel M., Levy E., Grubb A., Jucker M., Cystatin C modulates cerebral β -amyloidosis. Nature Genetics 2007 39 12 1437 1439 2-s2.0-36549085086 10.1038/ng.2007.23 (Pubitemid 350191342)
102. Mi W., Pawlik M., Sastre M., Jung S. S., Radvinsky D. S., Klein A. M., Sommer J., Schmidt S. D., Nixon R. A., Mathews P. M., Levy E., Cystatin C inhibits amyloid- β deposition in Alzheimer's disease mouse models. Nature Genetics 2007 39 12 1440 1442 2-s2.0-36549043900 10.1038/ng.2007.29 (Pubitemid 350191347)
103. Benussi L., Ghidoni R., Steinhoff T., Alberici A., Villa A., Mazzoli F., Nicosia F., Barbiero L., Broglio L., Feudatari E., Signorini S., Finckh U., Nitsch R. M., Binetti G., Alzheimer disease-associated cystatin C variant undergoes impaired secretion. Neurobiology of Disease 2003 13 1 15 21 2-s2.0-0038399757 10.1016/S0969-9961(03)00012-3 (Pubitemid 36561594)
104. Paraoan L., Ratnayaka A., Spiller D. G., Hiscott P., White M. R. H., Grierson I., Unexpected intracellular localization of the AMD-associated cystatin C variant. Traffic 2004 5 11 884 895 2-s2.0-7244221537 10.1111/j.1600-0854.2004.00230.x (Pubitemid 39433558)
105. Dehghan A., Köttgen A., Yang Q., Hwang S. J., Kao W. L., Rivadeneira F., Boerwinkle E., Levy D., Hofman A., Astor B. C., Benjamin E. J., van Duijn C. M., Witteman J. C., Coresh J., Fox C. S., Association of three genetic loci with uric acid concentration and risk of gout: a genome-wide association study. The Lancet 2008 372 9654 1953 1961 2-s2.0-57049083981 10.1016/S0140-6736(08) 61343-4
106. McGeer E. G., McGeer P. L., Brain inflammation in Alzheimer disease and the therapeutic implications. Current Pharmaceutical Design 1999 5 10 821 836 2-s2.0-0032731763 (Pubitemid 29510788)
107. Akiyama H., Barger S., Barnum S., Bradt B., Bauer J., Cole G. M., Cooper N. R., Eikelenboom P., Emmerling M., Fiebich B. L., Finch C. E., Frautschy S., Griffin W. S. T., Hampel H., Hull M., Landreth G., Lue L. F., Mrak R., MacKenzie I. R., McGeer P. L., O'Banion M. K., Pachter J., Pasinetti G., Plata-Salaman C., Rogers J., Rydel R., Shen Y., Streit W., Strohmeyer R., Tooyoma I., van Muiswinkel F. L., Veerhuis R., Walker D., Webster S., Wegrzyniak B., Wenk G., Wyss-Coray T., Inflammation and Alzheimer's disease. Neurobiology of Aging 2000 21 3 383 421 2-s2.0-0034612175 10.1016/S0197-4580(00)00124-X (Pubitemid 30349107)
108. Alexander J. J., Anderson A. J., Barnum S. R., Stevens B., Tenner A. J., The complement cascade: Yin-Yang in neuroinflammationneuro-protection and -degeneration. Journal of Neurochemistry 2008 107 5 1169 1187 2-s2.0-55849114955 10.1111/j.1471-4159.2008.05668.x
109. Husemann J., Silverstein S. C., Expression of scavenger receptor class B, type I, by astrocytes and vascular smooth muscle cells in normal adult mouse and human brain and in Alzheimer's disease brain. American Journal of Pathology 2001 158 3 825 832 2-s2.0-0035101055 (Pubitemid 32221775)
110. Allaman I., Gavillet M., Bélanger M., Laroche T., Viertl D., Lashuel H. A., Magistretti P. J., Amyloid- β aggregates cause alterations of astrocytic metabolic phenotype: impact on neuronal viability. Journal of
111. Leissring M. A., The A β Cs of A β -cleaving proteases. The Journal of Biological Chemistry 2008 283 44 29645 29649 2-s2.0-57649178322 10.1074/jbc.R800022200
112. Turner A. J., Nalivaeva N. N., New insights into the roles of metalloproteinases in neurodegeneration and neuroprotection. International Review of Neurobiology 2007 82 113 135 2-s2.0-34547328074 10.1016/S0074-7742(07) 82006-X
113. Hoozemans J. J. M., van Haastert E. S., Veerhuis R., Arendt T., Scheper W., Eikelenboom P., Rozemuller A. J. M., Maximal COX-2 and ppRb expression in neurons occurs during early Braak stages prior to the maximal activation of astrocytes and microglia in Alzheimer's disease. Journal of Neuroinflammation 2005 2, article 27 2-s2.0-28344439699 10.1186/1742-2094-2-27 (Pubitemid 41715845)
114. Cagnin A., Brooks D. J., Kennedy A. M., Gunn R. N., Myers R., Turkheimer F. E., Jones T., Banati R. B., In-vivo measurement of activated microglia in dementia. The Lancet 2001 358 9280 461 467 2-s2.0-0035845283 10.1016/S0140-6736(01)05625-2 (Pubitemid 32769854)
115. Itagaki S., McGeer P. L., Akiyama H., Zhu S., Selkoe D., Relationship of microglia and astrocytes to amyloid deposits of Alzheimer disease. Journal of Neuroimmunology 1989 24 3 173 182 2-s2.0-0024436506 (Pubitemid 19271472)
116. Nicoll J. A., Barton E., Boche D., Neal J. W., Ferrer I., A β species removal after A β 42 immunization. Journal of Neuropathology and Experimental Neurology 2006 65 11 1040 1048 10.1097/01.jnen.0000240466.10758.ce (Pubitemid 44684661)
117. Glezer I., Simard A. R., Rivest S., Neuroprotective role of the innate immune system by microglia. Neuroscience 2007 147 4 867 883 2-s2.0-34547127632 10.1016/j.neuroscience.2007.02.055 (Pubitemid 47102534)
118. Liu Y., Walter S., Stagi M., Cherny D., Letiembre M., Schulz-Schaeffer W., Heine H., Penke B., Neumann H., Fassbender K., LPS receptor (CD14): a receptor for phagocytosis of Alzheimer's amyloid peptide. Brain 2005 128 8 1778 1789 2-s2.0-23444448277 10.1093/brain/awh531 (Pubitemid 41373649)
119. Tahara K., Kim H. D., Jin J. J., Maxwell J. A., Li L., Fukuchi K. I., Role of toll-like receptor signalling in A β uptake and clearance. Brain 2006 129 11 3006 3019 2-s2.0-33750576993 10.1093/brain/awl249 (Pubitemid 44684521)
120. Richard K. L., Filali M., Préfontaine P., Rivest S., Toll-like receptor 2 acts as a natural innate immune receptor to clear amyloid β 142 and delay the cognitive decline in a mouse model of Alzheimer's disease. Journal of Neuroscience 2008 28 22 5784 5793 2-s2.0-45949106077 10.1523/JNEUROSCI.1146- 08.2008
121. Du Y., Dodel R., Hampel H., Buerger K., Lin S., Eastwood B., Bales K., Gao F., Moeller H. J., Oertel W., Farlow M., Paul S., Reduced levels of amyloid β -peptide antibody in Alzheimer disease. Neurology 2001 57 5 801 805 2-s2.0-0035845614 (Pubitemid 32845498)
122. Maetzler W., Langkamp M., Lerche S., Godau J., Brockmann K., Lowered serum amyloid-beta142 autoantibodies in individuals with lifetime depression. Journal of Alzheimer's Disease 2012 32 1 95 100 10.3233/JAD-2012-120625
123. Britschgi M., Olin C. E., Johns H. T., Takeda-Uchimura Y., Lemieux M. C., Rufibach K., Rajadas J., Zhang H., Tomooka B., Robinson W. H., Clark C. M., Fagan A. M., Galasko D. R., Holtzman D. M., Jutel M., Kaye J. A., Lemere C. A., Leszek J., Li G., Peskind E. R., Quinn J. F., Yesavage J. A., Ghiso J. A., Wyss-Coray T., Neuroprotective natural antibodies to assemblies of amyloidogenic peptides decrease with normal aging and advancing Alzheimer's disease. Proceedings of the National Academy of Sciences of the United States of America 2009 106 29 12145 12150 2-s2.0-67749122581 10.1073/pnas.0904866106
124. Hampel H., Prvulovic D., Teipel S., Jessen F., Luckhaus C., Frölich L., Riepe M. W., Dodel R., Leyhe T., Bertram L., Hoffmann W., Faltraco F., The future of Alzheimer's disease: the next 10 years. Progress in Neurobiology 2011 95 4 718 728 2-s2.0-82755161992 10.1016/j.pneurobio.2011.11.008
125. Rinne J. O., Brooks D. J., Rossor M. N., Fox N. C., Bullock R., Klunk W. E., Mathis C. A., Blennow K., Barakos J., Okello A. A., de LIano S. R. M., Liu E., Koller M., Gregg K. M., Schenk D., Black R., Grundman M., 11C-PiB PET assessment of change in fibrillar amyloid- β load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. The Lancet Neurology 2010 9 4 363 372 2-s2.0-77949300796 10.1016/S1474-4422(10)70043-0
126. Maetzler W., Stapf A. K., Schulte C., Hauser A.-K., Lerche S., Wurster I., Schleicher E., Melms A., Berg D., Serum and cerebrospinal fluid uric acid levels in lewy body disorders: associations with disease occurrence and amyloid- β pathway. Journal of Alzheimer's Disease 2011 27 1 119 126 2-s2.0-80155190079 10.3233/JAD-2011-110587
127. Brody D. L., Magnoni S., Schwetye K. E., Spinner M. L., Esparza T. J., Stocchetti N., Zipfel G. J., Holtzman D. M., Amyloid- β dynamics correlate with neurological status in the injured human brain. Science 2008 321 5893 1221 1224 2-s2.0-50649114611 10.1126/science.1161591
128. Maetzler W., Stoycheva V., Schmid B., Schulte C., Hauser A. K., Brockmann K., Melms A., Gasser T., Berg D., Neprilysin activity in cerebrospinal fluid is associated with dementia and amyloid- β 42 levels in lewy body disease. Journal of Alzheimer's Disease 2010 22 3 933 938 2-s2.0-78650656088 10.3233/JAD-2010-101197
129. Maetzler W., Schmid B., Synofzik M., Schulte C., Riester K., Huber H., Brockmann K., Gasser T., Berg D., Melms A., The CST3 BB genotype and low cystatin C cerebrospinal fluid levels are associated with dementia in lewy body disease. Journal of Alzheimer's Disease 2010 19 3 937 942 2-s2.0-77149165424 10.3233/JAD-2010-1289
130. Iseki E., Marui W., Akiyama H., Uéda K., Kosaka K., Degeneration process of Lewy bodies in the brains of patients with dementia with Lewy bodies using α -synuclein-immunohistochemistry. Neuroscience Letters 2000 286 1 69 73 2-s2.0-0034717256 10.1016/S0304-3940(00)01090-9 (Pubitemid 30259123)
131. Ishizawa K., Komori T., Sasaki S., Arai N., Mizutani T., Hirose T., Microglial activation parallels system degeneration in multiple system atrophy. Journal of Neuropathology and Experimental Neurology 2004 63 1 43 52 2-s2.0-0347419472 (Pubitemid 38030232)
132. Stefanova N., Reindl M., Neumann M., Haass C., Poewe W., Kahle P. J., Wenning G. K., Oxidative stress in transgenic mice with oligodendroglial α -synuclein overexpression replicates the characteristic neuropathology of multiple system atrophy. American Journal of Pathology 2005 166 3 869 876 2-s2.0-14644417871 (Pubitemid 40315643)
133. Hishikawa N., Hashizume Y., Yoshida M., Niwa J. I., Tanaka F., Sobue G., Tuft-shaped astrocytes in Lewy body disease. Acta Neuropathologica 2005 109 4 373 380 2-s2.0-18344365433 10.1007/s00401-004-0967-3 (Pubitemid 40637309)
134. Terada S., Ishizu H., Yokota O., Tsuchiya K., Nakashima H., Ishihara T., Fujita D., Uéda K., Ikeda K., Kuroda S., Glial involvement in diffuse Lewy body disease. Acta Neuropathologica 2003 105 2 163 169 2-s2.0-0037313281 (Pubitemid 36798802)